Rodríguez-Domínguez A, Berings M, Rohrbach A, et al. - In a real-life setting, it was inquired if an enhanced allergen-specific immunotherapy (AIT) success may be ensured by stratifying patients with house dust mite (HDM) allergy according to molecular analysis. Experts analyzed serum as well as nasal secretion samples obtained from patients having HDM allergy (n = 24) (at baseline, 7, 15, 33, and 52 weeks) who had received 1 year of therapy with a well-defined subcutaneous AIT form (Alutard SQ 510), to examine IgE and IgG reactivity to 15 microarrayed HDM allergen molecules with ImmunoCAP Immuno-solid-phase Allergen Chip technology. They found the presence of protective IgG, which was induced by Alutard SQ 510, predominantly against Dermatophagoides pteronyssinus (Der p) 1 and Der p 2 and to a lesser extent to Der p 23, but not to the other crucial allergens such as Der p 5, Der p 7, and Der p 21, this implies better clinical efficacy of Alutard SQ 510 in patients sensitized only to Der p 1 and/or Der p 2 vs patients with additional IgE specificities. Overall, it was inferred that enhanced success of AIT may be achieved via stratification of patients with HDM allergy as per molecular sensitization profiles as well as molecular monitoring of AIT-induced IgG responses.